Table 1.

Univariate analysis of clinical factors and GPS for progression free survival (n = 402)

	Patients (%)	mPFS months (95% CI)	P-value
Age
<60	203 (50.5)	4.3 (3.8-4.7)	0.840
≥ 60	199 (49.5)	4.5 (3.9-5.1)
Gender
Male	293 (72.9)	4.5 (3.9-5.0)	0.381
Female	109 (27.1)	4.3 (3.6-4.9)
Liver Mets
Yes	125 (31.1)	4.1 (3.6-4.5)	0.243
No	277 (68.9)	4.6 (3.9-5.2)
Peritoneal Mets
Yes	159 (39.6)	4.3 (3.8-4.8)	0.128
No	243 (60.4)	4.6 (3.9-5.2)
Bone Mets
Yes	28 (7.0)	3.9 (2.4-5.3)	0.032
No	374 (93.0)	4.5 (4.0-5.0)
Albumin
<3.5	77 (19.2)	3.4 (2.2-4.5)	0.013
≥ 3.5	325 (80.8)	4.6 (4.1-5.2)
CRP
≤ 1	262 (65.1)	5.3 (4.5-6.0)	0.001
>1	140 (34.9)	3.4 (2.7-4.1)
ECOG PS
0-1	329 (81.8)	4.6 (4.0-5.1)	0.002
≥ 2	73 (48.2)	3.0 (2.0-3.9)
GPS
0	238 (59.2)	5.5 (4.8-6.2)	0.001
1	111 (27.6)	3.4 (2.7-4.1)
2	53 (13.2)	3.3 (2.0-4.7)

mPFS: median progression free survival, Mets: Metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score